Tenax Therapeutics Faces Securities Class Action Lawsuit
A class action targets Tenax Therapeutics over alleged investor losses. The lead plaintiff deadline is December 28, 2026.
New York law firm Bronstein Gewirtz & Grossman, LLC has announced a securities class action lawsuit against Tenax Therapeutics, Inc., a Nasdaq-listed biopharmaceutical company trading under the ticker TENX, according to a notice released October 30, 2026.
Investors who purchased TENX securities during the period spanning November 13, 2023 through August 7, 2026 may be eligible to participate in the litigation and potentially recover losses sustained during that window. The complaint seeks damages against the company on behalf of affected shareholders.
Read more Settle Lands Up to $100M Financing Deal With 3Jane for Inventory Lending →
The lead plaintiff deadline — the last date by which an investor may petition the court to serve as the primary representative of the class — is December 28, 2026. Securities class actions typically allow any qualifying investor to join regardless of whether they serve as lead plaintiff, though lead plaintiffs generally have greater involvement in directing the litigation.
Class action securities suits of this nature allege that investors were harmed by material misstatements or omissions that artificially influenced a stock's price. The announcement did not specify the precise nature of the underlying allegations against Tenax Therapeutics, and no court has made a finding of liability at this stage.
Investors with questions about their eligibility or potential recovery are encouraged to consult legal counsel before the December deadline. Continue reading at All Financial Services & Investing.
